Login to Your Account



Clinic Roundup


Tuesday, February 26, 2013

• Cel-Sci Corp., of Vienna, Va., reported that its partner, Orient Europharma Co. Ltd., of Taipei, Taiwan, added two additional Taiwanese clinical centers in Cel-Sci's Phase III head and neck cancer trial for Multikine (Leukocyte Interleukin, Injection), including the China Medical University Hospital, of Taichung, Taiwan, and the Buddhist Tzu Chi General Hospital, of Hualian, Taiwan.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription